Gh Quote Stock
Guardant Health Inc. (NAS) | 2/1/2021 04:00 PM | ||||
| hide quote | detailed quote | options chain | |||
| Last: | Change: -0.09 | Open: | High: 157.77 | Low: | Volume: 933,999 |
| Percent Change: | Yield: n/a | P/E Ratio: | 52 Week Range: 55.90 to 168.52 | ||
2/1/2021 07:55 PM | 155.41 | n/a | 4,533 | ||
Guardant Health, Inc. Common Stock (GH) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. Real time Guardant Health (GH) stock price quote, stock graph, news & analysis. Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Find the latest GAMEHOST INC. (GH.TO) stock quote, history, news and other vital information to help you with your stock trading and investing. GH Complete Guardant Health Inc. Stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
12:32 AM ETHeadlines for Guardant Health Inc. (NAS:GH)
News for Guardant Health Inc.
Monday, January 11, 2021
08:37 AM ET
Guardant Health started at buy with $175 stock price target at Stifel Nicolaus MarketWatch
Wednesday, December 02, 2020
06:00 AM ET
DoorDash Is Set to Deliver SoftBank a Big HitThe Wall Street Journal Interactive Edition
Friday, May 15, 2020
08:00 AM ET
SoftBank’s Big Bets Are Hit Hard by CoronavirusThe Wall Street Journal Interactive Edition
Friday, December 13, 2019
07:00 AM ET
Gaurdant Health reiterated as outperform with $130 price target at Leerink MarketWatch
Monday, November 04, 2019
09:18 PM ET
WeWork Isn’t the Only Stumble for SoftBank’s Vision FundThe Wall Street Journal Interactive Edition
Monday, September 23, 2019
08:56 AM ET
What Drove SoftBank’s Vision Fund Up Is Dragging It DownThe Wall Street Journal Interactive Edition
Saturday, September 21, 2019
10:00 AM ET
WeWork Is a Headache for SoftBankThe Wall Street Journal Interactive Edition
Thursday, August 08, 2019
04:50 AM ET
AI Is Hot and SoftBank Is Offering Cash to BurnThe Wall Street Journal Interactive Edition
Wednesday, July 24, 2019
07:07 PM ET
SoftBank Looks to Goldman, Apple for Sequel to $100 Billion Vision FundThe Wall Street Journal Interactive Edition
Friday, May 10, 2019
07:54 AM ET
Guardant Health price target raised to $95 from $83 at SVB Leerink MarketWatch
Company Releases for Guardant Health Inc.
Gh Stock Quote
Gh Quote Stock Price
Wednesday, January 27, 2021
08:05 AM ET
Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer with Similar OutcomesBusinessWire - BZX
Monday, January 18, 2021
03:01 AM ET
Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in EuropeBusinessWire - BZX
Thursday, January 14, 2021
08:06 AM ET
Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal CancerBusinessWire - BZX
Wednesday, December 30, 2020
04:03 PM ET
Guardant Health to Participate in the 39th Annual J.P. Morgan Healthcare ConferenceBusinessWire - BZX
Friday, December 11, 2020
05:00 PM ET
Guardant Health Names Michael Bell as New Chief Financial OfficerBusinessWire - BZX
Monday, December 07, 2020
08:05 AM ET
Guardant Health Presents Data at San Antonio Breast Cancer Symposium Demonstrating Utility of GuardantINFORM™ Real-World Platform in Metastatic Breast CancerBusinessWire - BZX
Monday, November 16, 2020
11:22 PM ET
Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes OfferingBusinessWire - BZX
06:47 AM ET
Guardant Health, Inc. Announces Proposed Convertible Senior Notes OfferingBusinessWire - BZX
Thursday, November 05, 2020
04:49 PM ET
Guardant Health Reports Third Quarter 2020 Financial ResultsBusinessWire - BZX
Friday, October 16, 2020
04:05 PM ET
Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020BusinessWire - BZX
Gh After Hours Stock Price
The nascent liquid biopsy market may expand rapidly in the next five to 10 years, and one area of expansion--early cancer detection--could significantly change how cancer is treated. We believe liquid biopsies (a noninvasive method of analyzing tumors using fluids such as blood) may induce a paradigm shift in when cancer is detected and then treated, enabling earlier-stage treatments, where survival rates are higher and treatment costs per patient are lower. In general, a host of incentives for end users, practitioners, and payers could enable the widespread adoption of these tests, and we estimate the liquid biopsy market for early cancer detection could eventually exceed $70 billion in the U.S. alone, with global demand expanding the opportunity even further.
We cover three possible leaders in liquid biopsy for early cancer detection--narrow-moat Illumina, no-moat Exact Sciences, and no-moat Guardant Health. Based on our assessment of their valuations, we think the market is exuberant about liquid biopsy, so investors focused on value may have to pick and choose their entry points. Illumina, through its pending acquisition of Grail, could become the first mover and long-term leader in pan-cancer biopsies (for multiple cancers in one test). After further research into Illumina's opportunities with the Grail acquisition, which is scheduled to close in mid-2021, we recently increased our fair value estimate to $343 per share from $285. In our base scenario, we assume that liquid biopsy for the early detection of cancer succeeds with Illumina and its liquid biopsy peers, cumulatively reaching about $12 billion of annual sales in pan-cancer by the end of our 10-year forecast, and we assume that Illumina accounts for over half of that revenue potential with its first-mover and technology advantages. With Grail, we think Illumina's EPS growth can accelerate from the midteens in the next couple of years to over 40% compounded annually during the five years ended in 2027.